{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T04:16:50Z","timestamp":1744949810549,"version":"3.40.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-13990-8","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T16:12:51Z","timestamp":1744906371000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CD5 and p53 immunohistochemistry: valuable prediction method in molecular typing of CD5-positive diffuse large B-cell lymphoma"],"prefix":"10.1186","volume":"25","author":[{"given":"Han","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huaxiong","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danju","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuhui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangliang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beibei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaona","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiu","family":"Nie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"issue":"25","key":"13990_CR1","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1056\/NEJMoa012914","volume":"346","author":"A Rosenwald","year":"2002","unstructured":"Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937\u201347.","journal-title":"N Engl J Med"},{"key":"13990_CR2","doi-asserted-by":"crossref","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720\u201348.","DOI":"10.1038\/s41375-022-01620-2"},{"issue":"9","key":"13990_CR3","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJMra2027612","volume":"384","author":"LH Sehn","year":"2021","unstructured":"Sehn LH, Salles G. Diffuse large B-Cell lymphoma. N Engl J Med. 2021;384(9):842\u201358.","journal-title":"N Engl J Med"},{"issue":"5","key":"13990_CR4","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/JLB.MR0618-226R","volume":"105","author":"E Burgueno-Bucio","year":"2019","unstructured":"Burgueno-Bucio E, Mier-Aguilar CA, Soldevila G. The multiple faces of CD5. J Leukoc Biol. 2019;105(5):891\u2013904.","journal-title":"J Leukoc Biol"},{"issue":"5","key":"13990_CR5","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1093\/ajcp\/aqz207","volume":"153","author":"N Patel","year":"2020","unstructured":"Patel N, Durkin L, Bodo J, Hsi ED. Immunohistochemical expression of lymphoid enhancer binding factor 1 in CD5-Positive marginal zone, lymphoplasmacytic, and follicular lymphomas. Am J Clin Pathol. 2020;153(5):646\u201355.","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"13990_CR6","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1136\/jcp-2022-208603","volume":"77","author":"Y Li","year":"2024","unstructured":"Li Y, Wang G, Liu E, Zhang D, Zhang Y, Jian X, et al. Clinicopathological features of CD5-positive Splenic marginal zone lymphoma. J Clin Pathol. 2024;77(6):421\u20135.","journal-title":"J Clin Pathol"},{"issue":"7","key":"13990_CR7","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1093\/annonc\/mdq627","volume":"22","author":"K Miyazaki","year":"2011","unstructured":"Miyazaki K, Yamaguchi M, Suzuki R, Kobayashi Y, Maeshima AM, Niitsu N, et al. CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab. Ann Oncol. 2011;22(7):1601\u20137.","journal-title":"Ann Oncol"},{"issue":"4","key":"13990_CR8","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1002\/hon.2657","volume":"37","author":"P Zhao","year":"2019","unstructured":"Zhao P, Li L, Zhou S, Qiu L, Qian Z, Liu X, et al. CD5 expression correlates with inferior survival and enhances the negative effect of p53 overexpression in diffuse large B-cell lymphoma. Hematol Oncol. 2019;37(4):360\u20137.","journal-title":"Hematol Oncol"},{"issue":"8","key":"13990_CR9","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.3324\/haematol.12810","volume":"93","author":"M Yamaguchi","year":"2008","unstructured":"Yamaguchi M, Nakamura N, Suzuki R, Kagami Y, Okamoto M, Ichinohasama R, et al. De Novo CD5\u2009+\u2009diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients. Haematologica. 2008;93(8):1195\u2013202.","journal-title":"Haematologica"},{"issue":"19","key":"13990_CR10","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.1002\/cncr.34405","volume":"128","author":"S Ma","year":"2022","unstructured":"Ma S, Zhang B, Lu T, Li D, Li T, Shen Z, et al. Value of the prognostic nutritional index (PNI) in patients with newly diagnosed, CD5-positive diffuse large B-cell lymphoma: A multicenter retrospective study of the Huaihai lymphoma working group. Cancer. 2022;128(19):3487\u201394.","journal-title":"Cancer"},{"issue":"11","key":"13990_CR11","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1097\/PAS.0000000000001957","volume":"46","author":"W Sang","year":"2022","unstructured":"Sang W, Ma Y, Wang X, Ma Y, Shen Z, Gu W, et al. Clinicopathologic features and genomic signature of de Novo CD5\u2009+\u2009Diffuse large B-Cell lymphoma: A multicenter collaborative study. Am J Surg Pathol. 2022;46(11):1533\u201344.","journal-title":"Am J Surg Pathol"},{"issue":"6769","key":"13990_CR12","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503\u201311.","journal-title":"Nature"},{"issue":"1","key":"13990_CR13","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275\u201382.","journal-title":"Blood"},{"key":"13990_CR14","doi-asserted-by":"publisher","first-page":"941347","DOI":"10.3389\/fonc.2022.941347","volume":"12","author":"D Ma","year":"2022","unstructured":"Ma D, Ma Y, Ma Y, Liu J, Gu Y, Liu N, et al. Molecular subtyping of CD5\u2009+\u2009diffuse large B-cell lymphoma based on DNA-targeted sequencing and Lymph2Cx. Front Oncol. 2022;12:941347.","journal-title":"Front Oncol"},{"issue":"2","key":"13990_CR15","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s12185-015-1812-2","volume":"102","author":"K Miyazaki","year":"2015","unstructured":"Miyazaki K, Yamaguchi M, Imai H, Kobayashi K, Tamaru S, Kobayashi T, et al. Gene expression profiling of diffuse large B-Cell lymphomas supervised by CD5 expression. Int J Hematol. 2015;102(2):188\u201394.","journal-title":"Int J Hematol"},{"issue":"15","key":"13990_CR16","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-Cell lymphoma. N Engl J Med. 2018;378(15):1396\u2013407.","journal-title":"N Engl J Med"},{"issue":"4","key":"13990_CR17","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","volume":"37","author":"GW Wright","year":"2020","unstructured":"Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020;37(4):551\u2013e568514.","journal-title":"Cancer Cell"},{"issue":"1","key":"13990_CR18","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41392-023-01358-y","volume":"8","author":"R Shen","year":"2023","unstructured":"Shen R, Fu D, Dong L, Zhang MC, Shi Q, Shi ZY, et al. Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma. Signal Transduct Target Ther. 2023;8(1):145.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"13990_CR19","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1186\/s12885-023-11513-x","volume":"23","author":"X Li","year":"2023","unstructured":"Li X, Luo D, Zhang L, Li Q, Fan J, Zhang J, et al. Accurate interpretation of p53 immunohistochemical patterns is a surrogate biomarker for TP53 alterations in large B-cell lymphoma. BMC Cancer. 2023;23(1):1008.","journal-title":"BMC Cancer"},{"issue":"2","key":"13990_CR20","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/modpathol.2016.178","volume":"30","author":"XJ Wang","year":"2017","unstructured":"Wang XJ, Medeiros LJ, Bueso-Ramos CE, Tang G, Wang S, Oki Y, et al. P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC\/BCL2 expression in diffuse large B-cell lymphoma. Mod Pathol. 2017;30(2):194\u2013203.","journal-title":"Mod Pathol"},{"issue":"19","key":"13990_CR21","doi-asserted-by":"publisher","first-page":"3986","DOI":"10.1182\/blood-2012-05-433334","volume":"120","author":"ZY Xu-Monette","year":"2012","unstructured":"Xu-Monette ZY, Wu L, Visco C, Tai YC, Tzankov A, Liu WM, et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an international DLBCL Rituximab-CHOP consortium program study. Blood. 2012;120(19):3986\u201396.","journal-title":"Blood"},{"issue":"4","key":"13990_CR22","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1309\/AJCPPHMZ6VHF0WQV","volume":"141","author":"Y Xie","year":"2014","unstructured":"Xie Y, Bulbul MA, Ji L, Inouye CM, Groshen SG, Tulpule A, et al. p53 expression is a strong marker of inferior survival in de Novo diffuse large B-cell lymphoma and May have enhanced negative effect with MYC coexpression: a single institutional clinicopathologic study. Am J Clin Pathol. 2014;141(4):593\u2013604.","journal-title":"Am J Clin Pathol"},{"issue":"12","key":"13990_CR23","doi-asserted-by":"publisher","first-page":"e584","DOI":"10.1002\/ctm2.584","volume":"11","author":"MC Zhang","year":"2021","unstructured":"Zhang MC, Fang Y, Xu PP, Dong L, Shen R, Huang YH, et al. Clinical efficacy and tumour microenvironment influence of decitabine plus R-CHOP in patients with newly diagnosed diffuse large B-Cell lymphoma: phase 1\/2 and biomarker study. Clin Transl Med. 2021;11(12):e584.","journal-title":"Clin Transl Med"},{"issue":"4","key":"13990_CR24","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1200\/JCO.21.02143","volume":"40","author":"R Shouval","year":"2022","unstructured":"Shouval R, Alarcon Tomas A, Fein JA, Flynn JR, Markovits E, Mayer S, et al. Impact of TP53 genomic alterations in large B-Cell lymphoma treated with CD19-Chimeric antigen receptor T-Cell therapy. J Clin Oncol. 2022;40(4):369\u201381.","journal-title":"J Clin Oncol"},{"issue":"25","key":"13990_CR25","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1182\/blood-2015-03-630947","volume":"126","author":"SM O\u2019Brien","year":"2015","unstructured":"O\u2019Brien SM, Lamanna N, Kipps TJ, Flinn I, Zelenetz AD, Burger JA, et al. A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia. Blood. 2015;126(25):2686\u201394.","journal-title":"Blood"},{"key":"13990_CR26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ijbiomac.2021.09.188","volume":"192","author":"LL Chen","year":"2021","unstructured":"Chen LL, Wang WJ. p53 regulates lipid metabolism in cancer. Int J Biol Macromol. 2021;192:45\u201354.","journal-title":"Int J Biol Macromol"},{"issue":"15","key":"13990_CR27","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1200\/JCO.18.02403","volume":"37","author":"A Younes","year":"2019","unstructured":"Younes A, Sehn LH, Johnson P, Zinzani PL, Hong X, Zhu J, et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in Non-Germinal center B-Cell diffuse large B-Cell lymphoma. J Clin Oncol. 2019;37(15):1285\u201395.","journal-title":"J Clin Oncol"},{"issue":"12","key":"13990_CR28","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/j.ccell.2021.10.006","volume":"39","author":"WH Wilson","year":"2021","unstructured":"Wilson WH, Wright GW, Huang DW, Hodkinson B, Balasubramanian S, Fan Y, et al. Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. Cancer Cell. 2021;39(12):1643\u2013e16531643.","journal-title":"Cancer Cell"},{"issue":"14","key":"13990_CR29","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1182\/blood.2023019865","volume":"142","author":"E Mandato","year":"2023","unstructured":"Mandato E, Yan Q, Ouyang J, Paczkowska J, Qin Y, Hao Y, et al. MYD88L265P augments proximal B-cell receptor signaling in large B-cell lymphomas via an interaction with DOCK8. Blood. 2023;142(14):1219\u201332.","journal-title":"Blood"},{"issue":"4","key":"13990_CR30","doi-asserted-by":"publisher","first-page":"e7005","DOI":"10.1002\/cam4.7005","volume":"13","author":"T Deng","year":"2024","unstructured":"Deng T, Zhang S, Xiao M, Gu J, Huang L, Zhou X. A single-centre, real-world study of BTK inhibitors for the initial treatment of MYD88(mut) \/CD79B(mut) diffuse large B-cell lymphoma. Cancer Med. 2024;13(4):e7005.","journal-title":"Cancer Med"},{"issue":"12","key":"13990_CR31","first-page":"1010","volume":"43","author":"YF Shi","year":"2022","unstructured":"Shi YF, Gao ZF, Li XH, Guo LG, Zheng QL, Long MP, et al. [Investigation for pathological interpretation criteria and its prognostic value for P53 expression in Chinese diffuse large B-cell lymphoma]. Zhonghua Xue Ye Xue Za Zhi. 2022;43(12):1010\u20135.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13990-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-13990-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13990-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T16:12:52Z","timestamp":1744906372000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-13990-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13990"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-13990-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,17]]},"assertion":[{"value":"30 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our study complied with the Declaration of Helsinki and the ethical standards of the institutional and national research committees. Ethical approval was granted by the Ethics Committee of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, which waived the need for informed consent due to the retrospective study design.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"726"}}